cdc-assay-app-note1920x640
Application Note

Optimization of complement-dependent cytotoxicity assay on OncoSignature cell lines

Screening candidate mAbs for complement-dependent cytotoxicity (CDC) activity represents a crucial step in the development pipeline of successful therapeutics.

In this application note, we present how our complement-dependent cytotoxicity (CDC) assay offering can help drug screening efforts by leveraging our semi-automated screening platform and OncoSignature™ cell panel.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Optimization of complement-dependent cytotoxicity assay on OncoSignature cell lines

Download Application Note